Alithea Bio attending the 8th International Neoantigen Summit

We’re excited to announce that Alithea Biotechnology will be attending the 8^th International Neoantigen Summit, taking place on 24^th till the 26^th of June in Amsterdam, The Netherlands. As one of the leading global gatherings focused on the development of neoantigen vaccines and immunotherapies, this summit brings together cutting-edge science, groundbreaking technologies, and the brightest minds in oncology.

At Alithea, our mission is to empower biopharma with the world’s most advanced HLA-peptide data platform to accelerate (neo)antigen discovery, validation, and safety profiling. To further support drug development programs, we are launching our HLA-typed biorepository, ready for neoepitope validation in human tissues, significantly reducing the time required for tissue sourcing and HLA typing. The Neoantigen Summit is a key opportunity for us to connect with fellow scientists, collaborators, and industry leaders to share insights, explore challenges, and accelerate innovation in the field.

HLA-Compass comprises 4425 samples, 1.56 Million HLA peptides, 19 Million identifications, 34 healthy organs, 31 tumor indications and over 60 cell lines.

HLA-Compass can be used to validate the specificity of your HLA peptide targets and discover novel ones. HLA-Compass can be used to validate the specificity of your HLA peptide targets and discover novel ones. Alithea Bio has already discovered promising targets using HLA-Compass, highlighting its real-world effectiveness.

HLA-Compass can be used to evaluate the safety risks of anti-HLA peptide therapeutics. Several functionalities allow you to screen for sequences that may be targeted in healthy tissues. The figure highlights titin-derived peptides potentially causing severe cardiac toxicity.

Our team will be on-site and eager to meet with other pioneers committed to improving outcomes for cancer patients around the world.

Let’s connect during the summit! Reach out to us at the Booth No. 5